In the open study of ATH434 the volumetrics seems to be an excellent measurement evaluating the progression of neurodegeneration. Correspondingly volumetric measures will be used when evaluating AD drugs. Now the degeneration of cholinergic nerves will be measured by volumetric, not dopaminergic degeneration as in PD.
Forebrain atrophy in early AD, by Masters et al, page-2
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $1.937K | 645.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 78 | 92763980 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 330773 | 1 |
View Market Depth
| Last trade - 10.00am 15/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |